Home    Back

299. Cystic fibrosis
1,592 clinical trials,   1,539 drugs   (DrugBank: 255 drugs),   81 drug target genes,   162 drug target pathways

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
15 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2006-006693-24-CZ
(EUCTR)		16/07/200809/05/2007A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic FibrosisA Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10.000 children. In cystic fibrosis chloride transport across the respiratory epithelium is deficient, so the mucus contains less water and its viscosity is abnormally increased. Moli1901 corrects the abnormal transport of chloride thereby reducing the formation of mucus plugs and improving clearance.
MedDRA version: 9.1;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung		Product Name: Moli1901 (2622U90, duramycin)
Product Code: Moli1901
INN or Proposed INN: Not available
Other descriptive name: 2622U90 Duramycin		AOP Orphan Pharmaceuticals AGNULLNot RecruitingFemale: yes
Male: yes		160Hungary;Germany;Czech Republic;France;Spain;Italy;Austria;Sweden
2EUCTR2006-006693-24-IT
(EUCTR)		31/01/200812/11/2007A randomized, double blind, placebo controlled, dose-finding study to evaluate the efficacy and safety of aerosolized Moli1901 in adolescents (12 years of age or older) and adults with cystic fibrosis - NDA randomized, double blind, placebo controlled, dose-finding study to evaluate the efficacy and safety of aerosolized Moli1901 in adolescents (12 years of age or older) and adults with cystic fibrosis - ND Cystic fibrosis
MedDRA version: 6.1;Level: PT;Classification code 10011763		Product Name: DURAMYCIN
Product Code: MOLI 1901		AOP ORPHAN PHARMACEUTICALSNULLNot RecruitingFemale: yes
Male: yes		160Hungary;Germany;Czech Republic;France;Spain;Italy;Austria;Sweden
3EUCTR2006-006693-24-ES
(EUCTR)		21/01/200814/09/2007Estudio aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis, para evaluar la eficacia y la seguridad de Moli1901 aerosol en adolescentes (12 años de edad o más) y adultos con fibrosis quística - MOLIEstudio aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis, para evaluar la eficacia y la seguridad de Moli1901 aerosol en adolescentes (12 años de edad o más) y adultos con fibrosis quística - MOLI La FQ es la enfermedad hereditaria mortal más frecuente en la población caucásica, afectando a unos 4 de cada 10.000 niños. En la fibrosis quística, el transporte de cloro a través del epitelio respiratorio es deficiente, de manera que la mucosidad contiene menos agua y su viscosidad está aumentada de manera anormal. Se puede suponer que Moli1901 corrige el transporte anormal de cloro y agua en los pulmones y de ese modo reduce la formación de tapones de mucosidad y aumenta el aclaramiento.
MedDRA version: 9.1;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung		Product Name: Moli1901 (2622U90, duramycin)
Product Code: Moli1901		AOP Orphan Pharmaceuticals AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		160Hungary;Germany;Czech Republic;France;Spain;Italy;Austria;Sweden
4NCT00671736
(ClinicalTrials.gov)		October 200730/4/2008Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic FibrosisA Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults With Cystic FibrosisCystic FibrosisDrug: Moli1901;Drug: Moli1901 placeboAOP Orphan Pharmaceuticals AGNULLCompleted12 YearsN/ABoth160Phase 2Austria
5EUCTR2006-006693-24-DE
(EUCTR)		29/08/200729/05/2007A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic FibrosisA Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10.000 children. In cystic fibrosis chloride transport across the respiratory epithelium is deficient, so the mucus contains less water and its viscosity is abnormally increased. Moli1901 corrects the abnormal transport of chloride thereby reducing the formation of mucus plugs and improving clearance.
MedDRA version: 9.1;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung		Product Name: Moli1901 (2622U90, duramycin)
Product Code: Moli1901
INN or Proposed INN: Not available
Other descriptive name: 2622U90 Duramycin		AOP Orphan Pharmaceuticals AGNULLNot RecruitingFemale: yes
Male: yes		160Phase 2;Phase 3France;Hungary;Czech Republic;Poland;Spain;Austria;Germany;Italy;Sweden
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6EUCTR2006-006693-24-FR
(EUCTR)		23/08/200716/05/2007A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic FibrosisA Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10.000 children. In Cystic Fibrosis chloride transport accross the respiratory epithelium is deficient, so the mucus contains less water and its viscosity is abnormally increased. Moli 1901 corrects the abnormal transport of chloride thereby reducing the formation of mucus plugs and improving clearance.Product Name: Moli 1901 (2622U90, duramycin)
Product Code: Moli 1901		AOP Orphan Pharmaceuticals AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		160Hungary;Germany;Czech Republic;France;Spain;Italy;Austria;Sweden
7EUCTR2006-006693-24-SE
(EUCTR)		16/08/200702/07/2007A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic FibrosisA Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10.000 children. In cystic fibrosis chloride transport across the respiratory epithelium is deficient, so the mucus contains less water and its viscosity is abnormally increased. Moli1901 corrects the abnormal transport of chloride thereby reducing the formation of mucus plugs and improving clearance.
MedDRA version: 9.1;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung		Product Name: Moli1901 (2622U90, duramycin)
Product Code: Moli1901		AOP Orphan Pharmaceuticals AGNULLNot RecruitingFemale: yes
Male: yes		160Hungary;Germany;Czech Republic;France;Spain;Italy;Austria;Sweden
8EUCTR2006-006693-24-HU
(EUCTR)		27/07/200718/06/2007A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic FibrosisA Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10.000 children. In cystic fibrosis chloride transport across the respiratory epithelium is deficient, so the mucus contains less water and its viscosity is abnormally increased. Moli1901 corrects the abnormal transport of chloride thereby reducing the formation of mucus plugs and improving clearance.
MedDRA version: 9.1;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung		Product Name: Moli1901 (2622U90, duramycin)
Product Code: Moli1901		AOP Orphan Pharmaceuticals AGNULLNot RecruitingFemale: yes
Male: yes		160Hungary;Germany;Czech Republic;France;Spain;Italy;Austria;Sweden
9EUCTR2006-006693-24-AT
(EUCTR)		09/05/200711/01/2007A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic FibrosisA Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10.000 children. In cystic fibrosis chloride transport across the respiratory epithelium is deficient, so the mucus contains less water and its viscosity is abnormally increased. Moli1901 corrects the abnormal transport of chloride thereby reducing the formation of mucus plugs and improving clearance.
MedDRA version: 9.1;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung		Product Name: Moli1901 (2622U90, duramycin)
Product Code: Moli1901		AOP Orphan Pharmaceuticals AGNULLNot RecruitingFemale: yes
Male: yes		160Hungary;Germany;Czech Republic;France;Spain;Italy;Austria;Sweden
10EUCTR2005-005594-29-HU
(EUCTR)		31/10/200619/06/2006A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic FibrosisA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis Cystic FibrosisProduct Name: Moli1901
Product Code: Moli1901
Other descriptive name: Duramycin, 2622U90		AOP Orphan Pharmaceuticals AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		360Hungary;Czech Republic
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
11EUCTR2005-005594-29-CZ
(EUCTR)		04/10/200602/08/2006A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic FibrosisA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis Cystic FibrosisProduct Name: Moli1901
Product Code: Moli1901
Other descriptive name: Duramycin, 2622U90		AOP Orphan Pharmaceuticals AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		360Hungary;Czech Republic
12EUCTR2005-005594-29-SK
(EUCTR)		14/09/200611/08/2006A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic FibrosisA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis Cystic FibrosisProduct Name: Moli1901
Product Code: Moli1901
Other descriptive name: Duramycin, 2622U90		AOP Orphan Pharmaceuticals AGNULLNot RecruitingFemale: yes
Male: yes		360Phase 2;Phase 3Czech Republic;Hungary;Slovakia
13EUCTR2005-004344-30-HU
(EUCTR)		10/05/200623/12/2005An Evaluation of the Safety and Tolerability of Multiple Dose Regimens of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis and Stable Lung DiseaseAn Evaluation of the Safety and Tolerability of Multiple Dose Regimens of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis and Stable Lung Disease Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10,000 children. In cystic fibrosis chloride transport across the respiratory epithelium is deficient, so the mucus contains less water and its viscosity is abnormally increased. Moli1901 corrects the abnormal transport of chloride ans water in the lungs thereby reducing the formation of mucus plugs and improving clearance.Product Name: Moli1901 (2622U90, duramycin)
Product Code: EU Orphan Designation Number EU/3/02/120
Other descriptive name: Duramycin, 2622U90		AOP Orphan Pharmaceuticals AGNULLNot RecruitingFemale: yes
Male: yes		18Hungary
14EUCTR2005-004344-30-AT
(EUCTR)		31/10/200526/09/2005An Evaluation of the Safety and Tolerability of Multiple Dose Regimens of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis and Stable Lung DiseaseAn Evaluation of the Safety and Tolerability of Multiple Dose Regimens of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis and Stable Lung Disease Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10,000 children. In cystic fibrosis chloride transport across the respiratory epithelium is deficient, so the mucus contains less water and its viscosity is abnormally increased. Moli1901 corrects the abnormal transport of chloride ans water in the lungs thereby reducing the formation of mucus plugs and improving clearance.Product Name: Moli1901 (2622U90, duramycin)
Product Code: EU Orphan Designation Number EU/3/02/120
Other descriptive name: Duramycin, 2622U90		AOP Orphan Pharmaceuticals AGNULLNot RecruitingFemale: yes
Male: yes		18Hungary;Austria
15EUCTR2006-006693-24-PL
(EUCTR)		11/10/2007A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic FibrosisA Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10.000 children. In cystic fibrosis chloride transport across the respiratory epithelium is deficient, so the mucus contains less water and its viscosity is abnormally increased. Moli1901 corrects the abnormal transport of chloride thereby reducing the formation of mucus plugs and improving clearance.
MedDRA version: 9.1;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung		Product Name: Moli1901 (2622U90, duramycin)
Product Code: Moli1901
INN or Proposed INN: Not available
Other descriptive name: 2622U90 Duramycin		AOP Orphan Pharmaceuticals AGNULLNAFemale: yes
Male: yes		160Phase 2France;Hungary;Czech Republic;Spain;Poland;Austria;Germany;Italy;Sweden

Back to top